Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study

2018 ◽  
Vol 5 (2) ◽  
pp. e82-e94 ◽  
Author(s):  
Caroline Dartigeas ◽  
Eric Van Den Neste ◽  
Julie Léger ◽  
Hervé Maisonneuve ◽  
Christian Berthou ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Open Label ◽  
Phase 3 ◽  
Rituximab Maintenance

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

2015 ◽  
Vol 16 (13) ◽  
pp. 1370-1379 ◽  
Author(s):  
Marinus H J van Oers ◽  
Kazimierz Kuliczkowski ◽  
Lukáš Smolej ◽  
Mario Petrini ◽  
Fritz Offner ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Open Label ◽  
Phase 3

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

The Lancet ◽  
2010 ◽  
Vol 376 (9747) ◽  
pp. 1164-1174 ◽  
Author(s):  
M Hallek ◽  
K Fischer ◽  
G Fingerle-Rowson ◽  
AM Fink ◽  
R Busch ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document